Presenters at the recent San Antonio Breast Cancer Symposium (SABCS; December 10–14, 2019) reported the latest findings in breast cancer research. NEJM Journal Watch Oncology and Hematology Editor-in-Chief Dr. William Gradishar was on hand to summarize results of the key studies. For more information on the meeting, please visit the SABCS website. For access to the abstracts, please visit the Abstract Viewer.
The 2019 San Antonio Breast Cancer Symposium produced exciting presentations that will lead to new options for patients with HER2-positive metastatic breast cancer. At least two of the presentations will likely lead to FDA approval of new drugs. The widespread use of HER2-directed therapy with trastuzumab, pertuzumab, and trastuzumab em…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)